State Street’s Intellia Therapeutics NTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $88.7M | Buy |
6,922,676
+503,840
| +8% | +$6.42M | ﹤0.01% | 1438 |
|
|
2025
Q4 | $57.7M | Buy |
6,418,836
+1,447,967
| +29% | +$19.9M | ﹤0.01% | 1662 |
|
|
2025
Q3 | $85.8M | Buy |
4,970,869
+931,584
| +23% | +$11.5M | ﹤0.01% | 1420 |
|
|
2025
Q2 | $37.9M | Sell |
4,039,285
-470,976
| -10% | -$3.87M | ﹤0.01% | 1828 |
|
|
2025
Q1 | $32.1M | Sell |
4,510,261
-695,437
| -13% | -$7.02M | ﹤0.01% | 1868 |
|
|
2024
Q4 | $60.7M | Buy |
5,205,698
+62,164
| +1% | +$970K | ﹤0.01% | 1629 |
|
|
2024
Q3 | $106M | Buy |
5,143,534
+780,754
| +18% | +$18M | ﹤0.01% | 1293 |
|
|
2024
Q2 | $97.6M | Sell |
4,362,780
-235,042
| -5% | -$5.6M | ﹤0.01% | 1277 |
|
|
2024
Q1 | $126M | Sell |
4,597,822
-138,039
| -3% | -$3.83M | 0.01% | 1158 |
|
|
2023
Q4 | $144M | Buy |
4,735,861
+1,002,936
| +27% | +$28.8M | 0.01% | 1052 |
|
|
2023
Q3 | $118M | Buy |
3,732,925
+240,134
| +7% | +$9.32M | 0.01% | 1078 |
|
|
2023
Q2 | $142M | Sell |
3,492,791
-46,847
| -1% | -$1.9M | 0.01% | 997 |
|
|
2023
Q1 | $132M | Sell |
3,539,638
-215,106
| -6% | -$8.44M | 0.01% | 1011 |
|
|
2022
Q4 | $131M | Buy |
3,754,744
+1,067,025
| +40% | +$50.7M | 0.01% | 1002 |
|
|
2022
Q3 | $150M | Sell |
2,687,719
-456,092
| -15% | -$28.3M | 0.01% | 856 |
|
|
2022
Q2 | $163M | Buy |
3,143,811
+746,284
| +31% | +$37.9M | 0.01% | 848 |
|
|
2022
Q1 | $174M | Buy |
2,397,527
+556,076
| +30% | +$47.1M | 0.01% | 922 |
|
|
2021
Q4 | $218M | Buy |
1,841,451
+179,721
| +11% | +$22.5M | 0.01% | 820 |
|
|
2021
Q3 | $223M | Sell |
1,661,730
-116,612
| -7% | -$17.7M | 0.01% | 780 |
|
|
2021
Q2 | $288M | Sell |
1,778,342
-50,297
| -3% | -$3.92M | 0.02% | 696 |
|
|
2021
Q1 | $147M | Sell |
1,828,639
-414,101
| -18% | -$27.8M | 0.01% | 957 |
|
|
2020
Q4 | $122M | Sell |
2,242,740
-815,858
| -27% | -$29.6M | 0.01% | 998 |
|
|
2020
Q3 | $60.8M | Buy |
3,058,598
+739,310
| +32% | +$15.4M | ﹤0.01% | 1321 |
|
|
2020
Q2 | $48.8M | Buy |
2,319,288
+594,605
| +34% | +$10.1M | ﹤0.01% | 1479 |
|
|
2020
Q1 | $21.1M | Buy |
1,724,683
+31,214
| +2% | +$421K | ﹤0.01% | 1811 |
|
|
2019
Q4 | $24.8M | Sell |
1,693,469
-132,848
| -7% | -$1.85M | ﹤0.01% | 1991 |
|
|
2019
Q3 | $24.4M | Sell |
1,826,317
-21,963
| -1% | -$350K | ﹤0.01% | 1942 |
|
|
2019
Q2 | $30.3M | Buy |
1,848,280
+70,445
| +4% | +$1.11M | ﹤0.01% | 1822 |
|
|
2019
Q1 | $30.4M | Sell |
1,777,835
-536,595
| -23% | -$8M | ﹤0.01% | 1772 |
|
|
2018
Q4 | $31.6M | Buy |
2,314,430
+247,333
| +12% | +$4.6M | ﹤0.01% | 1655 |
|
|
2018
Q3 | $59.2M | Sell |
2,067,097
-629,324
| -23% | -$18.3M | ﹤0.01% | 1415 |
|
|
2018
Q2 | $73.8M | Buy |
2,696,421
+1,154,809
| +75% | +$28M | 0.01% | 1245 |
|
|
2018
Q1 | $32.5M | Buy |
1,541,612
+386,542
| +33% | +$9.51M | ﹤0.01% | 1723 |
|
|
2017
Q4 | $22.2M | Buy |
1,155,070
+965,685
| +510% | +$22.3M | ﹤0.01% | 1977 |
|
|
2017
Q3 | $4.71M | Buy |
189,385
+24,587
| +15% | +$463K | ﹤0.01% | 2828 |
|
|
2017
Q2 | $2.64M | Buy |
164,798
+56,363
| +52% | +$788K | ﹤0.01% | 3018 |
|
|
2017
Q1 | $1.53M | Buy |
108,435
+16,080
| +17% | +$216K | ﹤0.01% | 3177 |
|
|
2016
Q4 | $1.21M | Sell |
92,355
-2,225
| -2% | -$33.4K | ﹤0.01% | 3242 |
|
|
2016
Q3 | $1.61M | Buy |
94,580
+23,706
| +33% | +$459K | ﹤0.01% | 3059 |
|
|
2016
Q2 | $1.51M | Buy |
+70,874
| New | +$1.89M | ﹤0.01% | 3133 |
|
Other funds holding NTLA
AIM
VPM
VCM
RP
State Street's NTLA Position: Q1 2026 in Review
State Street increased its Intellia Therapeutics (NTLA) stake by 7.8% in Q1 2026, buying an estimated $6.42M and bringing the position to 6,922,676 shares worth $88.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1438.
State Street first reported a position in NTLA in Q2 2016 and has held it in 40 quarters since. The position peaked at $288M in Q2 2021. 303 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.
- State Street held 6,922,676 shares of Intellia Therapeutics worth $88.7M as of Q1 2026.
- State Street bought 503,840 Intellia Therapeutics shares in Q1 2026, an estimated $6.42M.
- Intellia Therapeutics made up ﹤0.01% of State Street's portfolio in Q1 2026, its #1438 holding.
- State Street first reported a position in Intellia Therapeutics in Q2 2016 and has held it in 40 quarters since.
- State Street's Intellia Therapeutics position peaked at $288M in Q2 2021.
- 303 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.
Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.